logo

For the Inventor, By the Inventor

La Jolla, CA, United States of America

Ambrx, Inc.


USPTO Granted Patents = 117

% Expired Patents = 29.1



Trademarks = 2

Forward Citations = 1,519

Loading Chart...
Loading Chart...

89 inventors (with patents filed for the assignee):

goldMedal Nick Knudsen (36 out of 37 patents)

silverMedal Feng Tian (31 out of 37 patents)

bronzeMedal Vadim Kraynov (29 out of 32 patents)

4.  Thea Norman (29 out of 39 patents)

5.  Zhenwei Miao (28 out of 50 patents)

6.  Jason Pinkstaff (28 out of 28 patents)

7.  Ho Sung Cho (28 out of 29 patents)

8.  Anna-Maria A Hays Putnam (26 out of 26 patents)

9.  Junjie Liu (20 out of 38 patents)

10.  Troy Edward Wilson (17 out of 55 patents)

11.  Anna-Maria A Hays (15 out of 15 patents)

12.  Russell Driver (14 out of 15 patents)

13.  Lillian Skidmore (13 out of 13 patents)

14.  Thomas O Daniel (13 out of 15 patents)

15.  Stephanie Chu (12 out of 12 patents)


Core Competencies:
Antibody Drug Conjugates
Modified Polypeptides
Non-Natural Amino Acids
Protein Production
Therapeutic Uses
Human Growth Hormone
Relaxin Polypeptides
FGF-21 Variants
Bioconjugates
Transcription Methods
Erythropoietin Polypeptides
Suppressor tRNA

117 patents:

1. 12653897 - PEGYLATED PORCINE INTERFERON AND METHODS OF USE THEREOF (2026-06-16),
2. 12622944 - Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives (2026-05-12),
3. 12577575 - METHODS AND COMPOSITIONS FOR PROMOTING NON-NATURAL AMINO ACID-CONTAINING PROTEIN PRODUCTION (2026-03-17),
4. 12569566 - COMPOSITIONS CONTAINING, METHODS AND USES OF ANTIBODY-TLR AGONIST CONJUGATES (2026-03-10),
5. 12404512 - Method for optimizing antibody expression (2025-09-02),
6. 12377294 - Anti-CD3 antibody folate bioconjugates and their uses (2025-08-05),
7. 12286462 - Porcine G-CSF variants and their uses (2025-04-29),
8. 12059473 - Humanized anti-prostate -specific membrane antigen (PSMA) antibody drug conjugates (2024-08-13),
9. 12049485 - Interleukin-2 polypeptide conjugates and their uses (2024-07-30),
10. 12037405 - Anti-CD70 antibody drug conjugates (2024-07-16),
11. 11993637 - Modified FGF-21 polypeptides with non-naturally encoded amino acids (2024-05-28),
12. 11851662 - Methods and compositions for promoting non-natural amino acid-containing protein production (2023-12-26),
13. 11851488 - Anti-CD3-folate conjugates and their uses (2023-12-26),
14. 11786578 - Modified relaxin polypeptides and their uses (2023-10-17),
15. 11773150 - Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors (2023-10-03),
AMBRx, Inc. is a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformative protein therapeutics using an expanded genetic code technology. Their proprietary technology enables the site-specific incorporation of amino acids beyond the 20 naturally occurring ones, resulting in novel, optimized therapeutic proteins with enhanced properties. AMBRx aims to address unmet medical needs and deliver innovative treatments for cancer, metabolic disorders, and other serious diseases.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 15 2026

117 Patents

#5 in La Jolla, CA

#745 in California

#3,287 in US

#6,784 in the World

La Jolla, CA (US)
La Jolla, CA, United States of America

Ambrx, Inc.

Forward Citations = 1,519

89 inventors:

goldMedal Nick Knudsen (36 out of 37 patents)

silverMedal Feng Tian (31 out of 37 patents)

bronzeMedal Vadim Kraynov (29 out of 32 patents)

4.  Thea Norman (29 out of 39 patents)

5.  Zhenwei Miao (28 out of 50 patents)

Please report any incorrect information to [email protected]
Loading…